Researchers have identified a key enzyme that cancerous tumours rely on to grow and spread within the body. Described as cancer’s “Achilles Heel”, scientists believe that targeting this enzyme stops tumour cells from growing and spreading. The findings could accelerate the development of new treatments for solid-tumour cancers. Solid cancerous tumours rely on an available […]
ctDNA accurate at diagnosing rectal cancer relapse
Posted: 17th September 2021
Categories: Industry news
Combining circulating tumour DNA (ctDNA) with magnetic resonance imaging (MRI) can more accurately predict the likelihood of locally advanced rectal cancer (LARC) returning after treatment, Chinese scientists have found. In a new study published in PLOS Medicine, researchers describe how combining the techniques improved diagnosis and could improve treatment and outcomes for patients. In addition, […]
Measuring circulating tumour DNA can improve bladder cancer treatment
Posted: 1st September 2021
Categories: Industry news
The presence of circulating tumour DNA (ctDNA) is a crucial biomarker for patients with bladder cancer (urothelial carcinoma) researchers have found in a new study. Scientists suggest that post-operative screening for ctDNA could improve cancer treatments and patient outcomes. The authors hope the findings could help improve outcomes for bladder cancer and more broadly illustrates […]
Can brain tumours also be tested with a blood sample?
No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
Which test is the most comprehensive test?
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
How do online consultations work?
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.
Will online consultations take place via Zoom, Skype or another method?
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.